The ReSPECT-GBM™ phase I/IIa trial of rhenium-186 nanoliposome (186RNL) in recurrent glioma via convection enhanced delivery (CED) and planned phase IIb trial (ESMO 2022) - Jul 25, 2022 - Abstract #277O; Pres time: Sep 9, 2022; 02:00 PM - 02:10 PM; Location: 7.3.Q - Quimper Auditorium; "A RP2D of 22.3mCi/8.8mL was selected for patients with tumors of up to 15mL in the PIIb trial planned for 2022. The PIIb trial design and comparative survival data (synthetic control arm) will also be presented."
P1/2 data • P2b data • Brain Cancer • Glioma • Oncology • Solid Tumor
|
|
A.J. Brenner1; W.T. Phillips2; A. Bao3; M.H.H. Hedrick4; J.E. Michalek5; N. LaFrance6; T.R. Patel7; J. Weinberg8; J.R. Floyd9
|